NDLI: A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy

Content Provider	PubMed Central
Author	Song, Ying-chyi Liu, Hsueh-hung Chen, I-hua Chen, Hsin-wei Chong, Pele Leng, Chih-hsiang Liu, Shih-jen
Copyright Year	2014
Abstract	Synthetic lipopeptides have been widely used as vaccine adjuvants to enhance immune responses. The present study demonstrated that the tryptic N-terminal fragment of the lipoprotein rlipo-D1E3 (lipo-Nter) induces superior antitumor effects compared to a synthetic lipopeptide. The lipo-Nter was purified and formulated with protein or peptide vaccines to determine if lipo-Nter could be used as a novel adjuvant and could induce antitumor immunity in a cervical cancer model. Purified lipo-Nter activated the maturation of bone marrow-derived dendritic cells (BM-DCs), leading to the secretion of TNF- α through TLR2/6 but not TLR1/2. A recombinant mutant HPV16 E7 (rE7m) protein was mixed with lipo-Nter to immunize the mice; the anti-E7 antibody titers were increased, and the T helper cells were skewed toward the Th1 fate (increased IL-2 and decreased IL-5 secretion). Single-dose injection of rE7m and lipo-Nter inhibited tumor growth, but the injection of rE7m alone did not. Accordingly, lipo-Nter also enhanced the antitumor immunity of the E7-derived peptide but not the synthetic lipopeptide (Pam3CSK4). We demonstrated that the lipo-Nter of a bacterial-derived recombinant lipoprotein is a novel adjuvant that could be used for the development of a new generation of vaccines.
Related Links	http://dx.doi.org/10.1155/2014/349783
Starting Page	349783
File Format	PDF
ISSN	23146141
e-ISSN	23146141
Journal	BioMed Research International
Volume Number	2014
Language	English
Publisher	Hindawi Publishing Corporation
Publisher Date	2014-01-01
Access Restriction	Open
Rights Holder	Hindawi Publishing Corporation
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Microbiology Medicine Biochemistry, Genetics and Molecular Biology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy

“Adherent” versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy

Cancer Immunology and Immunotherapy

Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine

From Bench to Bedside: Immunotherapy for Prostate Cancer

Replicase activity of purified recombinant protein P2 of double-stranded RNA bacteriophage phi6.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy

Human Tumor Antigens and Cancer Immunotherapy

The zebrafish as a model for cancer

A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy

Similar Documents

Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy

“Adherent” versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy

Cancer Immunology and Immunotherapy

Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine

From Bench to Bedside: Immunotherapy for Prostate Cancer

Replicase activity of purified recombinant protein P2 of double-stranded RNA bacteriophage phi6.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy

Human Tumor Antigens and Cancer Immunotherapy

The zebrafish as a model for cancer

A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy